Literature DB >> 8405852

Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs.

D Henry1, A Dobson, C Turner.   

Abstract

BACKGROUND: We have assessed the extent to which the risk of serious gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) varies with the age and sex of recipients, use of aspirin or alcohol, administration by the oral or rectal route, and dose and choice of drug.
METHODS: A case-control study was performed with prospective recruitment of cases of gastrointestinal bleeding or ulcer perforation and age- and sex-matched controls. Information on preadmission drug use obtained by structured interview.
RESULTS: Six hundred forty-four patients and 1268 controls were recruited. The odds ratio for upper gastrointestinal complications in users compared with nonusers of NANSAIDs increased with age: < or = 59 years, odds ratio 2.0; 60-79 years, odds ratio 3.0; > or = 80 years, odds ratio 4.2; and was higher in women (5.4) than in men (1.9). There was a linear dose-response curve that was steeper in women than in men. Combined exposure suggested additive risks: NANSAIDs and aspirin, odds ratio 6.7; NANSAIDs and alcohol, odds ratio 6.0 NANSAIDs by the oral route were associated with an odds ratio of 2.3, compared with 11.4 with rectal administration. Piroxicam was associated with the highest risk, odds ratio 4.8; and ibuprofen the lowest risk, odds ratio 0.7.
CONCLUSIONS: A number of factors can alter the risk of major gastrointestinal complications with NANSAIDs and need to be considered when individual prescribing decisions are made.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405852     DOI: 10.1016/0016-5085(93)90952-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  46 in total

1.  Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.

Authors:  S Lugardon; M Lapeyre-Mestre; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2004-10-23       Impact factor: 2.953

2.  Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.

Authors:  Mai Duong; Francesco Salvo; Antoine Pariente; Abdelilah Abouelfath; Regis Lassalle; Cecile Droz; Patrick Blin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

3.  Anti-inflammatory drugs and variceal bleeding: a case-control study.

Authors:  V De Lédinghen; D Heresbach; O Fourdan; P Bernard; M P Liebaert-Bories; J B Nousbaum; A Gourlaouen; M C Becker; D Ribard; P Ingrand; C Silvain; M Beauchant
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 4.  Tolerability of topical NSAIDs in the elderly: do they really convey a safety advantage?

Authors:  J M Evans; T M MacDonald
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

5.  Serious upper gastrointestinal complications of NSAIDs and COX-2 selective agents.

Authors:  Guy Sisson; Ingvar Bjarnason
Journal:  Inflammopharmacology       Date:  2011-05-01       Impact factor: 4.473

Review 6.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

7.  Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.

Authors:  S C Lewis; M J S Langman; Joan-Ramon Laporte; John N S Matthews; Michael D Rawlins; Bengt-Erik Wiholm
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

8.  Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system.

Authors:  Wei Zou; Sachin S Devi; Erica Sparkenbaugh; Husam S Younis; Robert A Roth; Patricia E Ganey
Journal:  Toxicol Sci       Date:  2008-12-12       Impact factor: 4.849

9.  Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study.

Authors:  G R Lipscomb; N Wallis; G Armstrong; W D Rees
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

10.  Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.

Authors:  Patricia McGettigan; Pearline Han; Lisa Jones; Diana Whitaker; David Henry
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.